Dr Brooke Short
Lecturer
School of Medicine and Public Health (Medicine)
- Email:brooke.short@newcastle.edu.au
- Phone:02 4320 3627
Career Summary
Biography
Dr Brooke Short, MBBS(Hon), BSc(Biochem), BMedSc(Path), MMed, FRANZCP, is a Lecturer in Psychiatry and Clinical Academic Psychiatrist at Gosford Hospital, Australia. She is also the Program Coordinator for Psychiatry at the University of Newcastle and the University of New England, Joint Medical Program (Faculty of Health and Medicine).
Brooke's research interests are focused on improving the quality and safety of mental health services, evaluating patient comorbidity and healthcare culture, and enhancing psychiatric research capability. Brooke's initial research focused on schizophrenia and its pathogenesis. More recently her research has involved qualitative analysis, improvement science methodologies and the utilisation of artificial intelligence platforms in the mental health space. She has also had experience in health policy, holding positions at the World Health Organization and the NSW Ministry of Health. This has included enhancing community mental health services and access across Asian and African countries. In 2017, Brooke worked as a Psychiatry Fellow and clinical lead with the NSW Ministry of Health to develop a co-designed Quality and Safety Framework for NSW mental health services. She was awarded a Health Education Training institute (HETI) Mental Health Award for this work.
In collaboration with the Black Dog Institute and UNSW, she published the first systematic review exploring the safety and tolerability of ketamine as a treatment for depression, and has led the development of the Ketamine Side Effect Tool (KSET). She has also recently evaluated metabolic comorbidity in patients on antipsychotic medications and the need for increased screening and intervention for these people in the inpatient setting. She is a collaborator with the CCLHD Health Promotion Service and co-principal investigator on research exploring associations between tobacco use, mental health and smoking cessation interventions.
Recently she has been involved in research grants and collaborations with the Sydney Arts and Health Collective exploring and evaluating healthcare workplace culture, including using verbatim theatre as a stimulus for cultural change, hidden curriculum and burnout issues, and improving orientation for medical students transitioning to the clinical setting. She is currently working on machine learning platforms to both improve the delivery of mental health services as well as improve diagnostics and treatments.
LinkedIn Profile - https://www.linkedin.com/in/brooke-short-65a16655
Qualifications
- Master of Medicine, New South Wales Institute of Psychiatry
- Bachelor of Medical Science (Pathology), University of New South Wales
- Bachelor of Science (Biochemistry), University of New South Wales
- Bachelor of Medicine, Bachelor of Surgery, University of New South Wales
Keywords
- Clinical Academic
- Ketamine
- Mental Health
- Psychiatry
- Quality and Safety
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|
Professional appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 1/1/2009 - 1/10/2018 | Conjoint Lecturer | University of New South Wales School of Psychiatry, Faculty of Medicine Australia |
Teaching
| Code | Course | Role | Duration |
|---|---|---|---|
| MEDI6101A |
Integrated Medicine Faculty of Health and Medicine, The University of Newcastle |
Program Coordinator | 2/12/2019 - 4/1/2021 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Journal article (11 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 |
Short B, Dong V, Gálvez V, Vulovic V, Martin D, Bayes AJ, et al., 'Development of the Ketamine Side Effect Tool (KSET)', Journal of Affective Disorders, 266 615-620 (2020) [C1]
|
||||||||||
| 2019 |
Short B, Lambeth L, David M, Ryall M, Hood C, Pahalawatta U, Dawson A, 'An immersive orientation program to improve medical student integration and wellbeing', The Clinical Teacher, 16 323-328 (2019) [C1]
|
||||||||||
| 2019 |
Short B, Marr C, Wright M, 'A new paradigm for mental-health quality and safety: are we ready?', Australasian Psychiatry, 27 44-49 (2019) [C1]
|
||||||||||
| 2015 |
Weickert TW, Weinberg D, Lenroot R, Catts SV, Wells R, Vercammen A, et al., 'Adjunctive raloxifene treatment improves attention and memory in men and women with schizophrenia', Molecular Psychiatry, 20 685-694 (2015) [C1] There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator, ... [more] There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia. A selective estrogen receptor modulator, raloxifene, stimulates estrogen-like activity in brain and can improve cognition in older adults. The present study tested the extent to which adjunctive raloxifene treatment improved cognition and reduced symptoms in young to middle-age men and women with schizophrenia. Ninety-eight patients with a diagnosis of schizophrenia or schizoaffective disorder were recruited into a dual-site, thirteen-week, randomized, double-blind, placebo-controlled, crossover trial of adjunctive raloxifene treatment in addition to their usual antipsychotic medications. Symptom severity and cognition in the domains of working memory, attention/processing speed, language and verbal memory were assessed at baseline, 6 and 13 weeks. Analyses of the initial 6-week phase of the study using a parallel groups design (with 39 patients receiving placebo and 40 receiving raloxifene) revealed that participants receiving adjunctive raloxifene treatment showed significant improvement relative to placebo in memory and attention/processing speed. There was no reduction in symptom severity with treatment compared with placebo. There were significant carryover effects, suggesting some cognitive benefits are sustained even after raloxifene withdrawal. Analysis of the 13-week crossover data revealed significant improvement with raloxifene only in attention/processing speed. This is the first study to show that daily, oral adjunctive raloxifene treatment at 120 mg per day has beneficial effects on attention/processing speed and memory for both men and women with schizophrenia. Thus, raloxifene may be useful as an adjunctive treatment for cognitive deficits associated with schizophrenia.
|
||||||||||
| 2011 |
Vercammen A, Rushby JA, Loo C, Short B, Weickert CS, Weickert TW, 'Transcranial direct current stimulation influences probabilistic association learning in schizophrenia', SCHIZOPHRENIA RESEARCH, 131 198-205 (2011)
|
||||||||||
| 2011 |
Rushby JA, Vercammen A, Loo C, Short B, Weickert CS, Weickert TW, 'Frontal and Parietal Contributions to Probabilistic Association Learning', CEREBRAL CORTEX, 21 1879-1888 (2011)
|
||||||||||
| Show 8 more journal articles | |||||||||||
Conference (3 outputs)
| Year | Citation | Altmetrics | Link | ||
|---|---|---|---|---|---|
| 2019 |
Dawson A, Pahalawatta U, Short B, Lambeth L, David M, Ryall M, Hood C, 'Facilitating a successful transition from academic to clinical education for medical Students', Vienna Austria (2019)
|
||||
| 2019 |
Dawson A, Pahalawatta U, Turnbull S, newlands J, Buckland R, Willcocks J, Short B, 'Creating an Effective Hospital Culture: Collaboration between Education, Workforce and JMOs. Workshop', Canberra (2019)
|
||||
| 2018 |
Lambeth L, David M, Short B, Ryall M, Hood C, Dawson AC, 'Training the Central Coasts Future Doctors at BEACCHES', Central Coast (2018)
|
Grants and Funding
Summary
| Number of grants | 3 |
|---|---|
| Total funding | $124,000 |
Click on a grant title below to expand the full details for that specific grant.
20192 grants / $24,000
Central Coast Local Health District, Caring for Our Future Research Grant$20,000
Funding body: Central Coast Local Health District
| Funding body | Central Coast Local Health District |
|---|---|
| Scheme | Research |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2020 |
| GNo | |
| Type Of Funding | Other Public Sector - Local |
| Category | 2OPL |
| UON | N |
Faculty of Health and Medicine, University of Newcastle Travel Grant$4,000
Funding body: School of Medicine and Public Health, The University of Newcastle
| Funding body | School of Medicine and Public Health, The University of Newcastle |
|---|---|
| Scheme | Conference Presentation |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2019 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20171 grants / $100,000
Higher Education and Training Institute (HETI) Mental Health Research Award$100,000
Funding body: Higher Education and Training Institute (HETI)
| Funding body | Higher Education and Training Institute (HETI) |
|---|---|
| Scheme | NSW Health |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2018 |
| GNo | |
| Type Of Funding | C1600 - Aust Competitive - StateTerritory Govt |
| Category | 1600 |
| UON | N |
Research Supervision
Number of supervisions
Current Supervision
| Commenced | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2021 | PhD | Using Machine Learning to Assist Decision Making in the Assessment of Mental Health Consumers Presenting to Emergency Departments | PhD (Nursing), College of Health, Medicine and Wellbeing, The University of Newcastle | Co-Supervisor |
Dr Brooke Short
Position
Lecturer
School of Medicine and Public Health
College of Health, Medicine and Wellbeing
Focus area
Medicine
Contact Details
| brooke.short@newcastle.edu.au | |
| Phone | 02 4320 3627 |
Office
| Building | Training and Research Unit |
|---|---|
| Location | Gosford Hospital Cnr Henry Parry Drive and Margin Street Gosford, NSW 2250 Australia |